Literature DB >> 15115691

Cell cycle analysis of the CD133+ and CD133- cells isolated from umbilical cord blood.

Branka Grskovic1, Katharina Ruzicka, Alireza Karimi, Durdi Qujeq, Mathias M Müller.   

Abstract

BACKGROUND: Umbilical cord blood cells (stem/progenitor cells) exhibit high proliferative capacities leading to a large expansion of cells in appropriate cell culture conditions. The aim of this study was to evaluate by flow cytometry the cycling status of CD133+ and CD133- cells depending on various culture conditions, such as sera, stem cell factor (SCF), interleukin 3 (IL-3) and interleukin 6 (IL-6).
METHODS: An immunomagnetic system was used for cell separation. CD133+ and CD133- cells were seeded in Iscove's Modified Dulbecco's Medium (IMDM) with different serum concentrations and were stimulated with SCF (100 ng/ml), IL-3 (50 ng/ml) and IL-6 (50 ng/ml).
RESULTS: Our experiments demonstrated that immediately after separation, 96.75+/-0.58% of CD133+ cells and 97.04+/-1.76% of CD133- cells were in G0/G1-phase, while 2.02+/-0.38% and 0.88+/-0.52% were in the S-phase, respectively. Our data documented that CD133+ cells are more active than CD133- cells after the first week of cultivation (p<0.01). Statistically significant difference was found for CD133+ cells vs. CD133- cells after second week of cultivation in G0/G1- and S-phases under all tested conditions. A combination of 12.5% FCS+12.5% HS yielded the highest cell expansion for CD133+ cells; this was concomitant with highest percentage of S-phase and G2M-phase. Our data show that the medium with 25% HS was the best for cell expansion and cycling of the CD133- cells for the first week, followed by the 12.5% FCS+12.5% HS. After 2 weeks of cultivation, obviously 12.5% HS and 12.5% FCS+12.5% HS exhibited similar S-phase amounts in CD133- cells. A decrease of HS concentrations seemed to stimulate CD133- cells' S-phase after the second week.
CONCLUSIONS: Our data indicate that the source and the concentration of the serum used for cultivation have an impact on both cell populations: CD133+ cells are most comfortable with a combination of FCS and HS; CD133- cells prefer media-containing HS. Cell cycle status may be an important factor for defining cultivation strategies for stem cell expansion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115691     DOI: 10.1016/j.cccn.2004.01.023

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Ensheathing cell-conditioned medium directs the differentiation of human umbilical cord blood cells into aldynoglial phenotype cells.

Authors:  María Dolores Ponce-Regalado; Daniel Ortuño-Sahagún; Carlos Beas Zarate; Graciela Gudiño-Cabrera
Journal:  Hum Cell       Date:  2012-04-21       Impact factor: 4.174

Review 2.  Biochemical Aspects of Scaffolds for Cartilage Tissue Engineering; from Basic Science to Regenerative Medicine.

Authors:  Davood Yari; Mohammad H Ebrahimzadeh; Jebrail Movaffagh; Azadeh Shahroodi; Moein Shirzad; Durdi Qujeq; Ali Moradi
Journal:  Arch Bone Jt Surg       Date:  2022-03

3.  Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines.

Authors:  Marie Jaksch; Jorge Múnera; Ruchi Bajpai; Alexey Terskikh; Robert G Oshima
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

4.  Cancer stem cells in solid tumors: elusive or illusive?

Authors:  Yvonne Welte; James Adjaye; Hans R Lehrach; Christian Ra Regenbrecht
Journal:  Cell Commun Signal       Date:  2010-05-11       Impact factor: 5.712

5.  Characteristics of hematopoietic stem cells of umbilical cord blood.

Authors:  Anna Hordyjewska; Łukasz Popiołek; Anna Horecka
Journal:  Cytotechnology       Date:  2014-11-06       Impact factor: 2.058

6.  Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells from Umbilical Cord Blood.

Authors:  E V Sotnezova; E R Andreeva; A I Grigoriev; L B Buravkova
Journal:  Acta Naturae       Date:  2016 Jul-Sep       Impact factor: 1.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.